"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(Generic versions may still be available.)
There is no evidence that VERMOX® (mebendazole), even at high doses, is effective for hydatid disease. There have been rare reports of neutropenia and liver function elevations, including hepatitis, when VERMOX® (mebendazole) is taken for prolonged periods and at dosages substantially above those recommended.
Carcinogenesis and Mutagenesis
In carcinogenicity tests of mebendazole in mice and rats, no carcinogenic effects were seen at doses as high as 40 mg/kg given daily over two years. Dominant lethal mutation tests in mice showed no mutagenicity at single doses as high as 640 mg/kg. Neither the spermatocyte test, the F1 translocation test, nor the Ames test indicated mutagenic properties.
Impairment of Fertility
Use in Pregnancy
Pregnancy Category C. Mebendazole has shown embryotoxic and teratogenic activity in pregnant rats at single oral doses as low as 10 mg/kg. In view of these findings the use of VERMOX® (mebendazole) is not recommended in pregnant women. In humans, a post-marketing survey has been done of a limited number of women who inadvertently had consumed VERMOX® (mebendazole) during the first trimester of pregnancy. The incidence of spontaneous abortion and malformation did not exceed that in the general population. In 170 deliveries on term, no teratogenic risk of VERMOX® (mebendazole) was identified. During pregnancy, especially during the first trimester, VERMOX® (mebendazole) should be used only if the potential benefit justifies the potential risk to the fetus.
It is not known whether VERMOX® (mebendazole) is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VERMOX® (mebendazole) is administered to a nursing woman.
The drug has not been extensively studied in children under two years; therefore, in the treatment of children under two years the relative benefit/ risk should be considered.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/13/2008
Additional Vermox Information
Vermox - User Reviews
Vermox User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.